Scholar Rock Holding Corporation
SRRK
Rang in aandelen
#3308
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Aandeelprijs
$43.16
Laatst gesynchroniseerd: 2026-10-21
Marktkapitalisatie
$5.26B
Verandering (1 dag)
4.35%
Verandering (1 jaar)
51.33%
Land
US
Handel Scholar Rock Holding Corporation (SRRK)
Categorie
Healthcare
Koersgeschiedenis voor Scholar Rock Holding Corporation (SRRK)
Hoogste slotkoers: $42.18 op 2026-10-01
Laagste slotkoers: $16.12 op 2018-05-01
Laagste slotkoers: $16.12 op 2018-05-01
Koersgeschiedenis van Scholar Rock Holding Corporation van 2018 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | 3.69% |
| 2025 | 4.21% |
| 2024 | 139.27% |
| 2023 | 123.69% |
| 2022 | -68.52% |
| 2021 | -46.82% |
| 2020 | 347.42% |
| 2019 | -54.48% |
| 2018 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $765.49 | 8.80% |
CH
|
